Testing natural killer cells for leftover lung nodules
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new treatment using your own immune cells (called NK cells) to fight leftover high-risk lung nodules that cannot be surgically removed. It is for people who have already had some cancerous nodules removed and are looking for another option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have had multiple high-risk lung nodules removed and found to be cancer, and you still have at least one high-risk nodule that cannot be removed again.
- That remaining nodule is not suitable for other treatments, or those treatments have already failed.
- You do not have serious bleeding problems, like a history of bleeding in the stomach or trouble with blood clotting.
- You have not had a heart attack, unstable angina, or heart failure symptoms in the last 6 months.
- You have not taken part in another clinical trial in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced testing methods on lung nodules to better tell if they are benign (not cancer) or malignant (cancer). It may help improve diagnosis for people scheduled for surgery to remove a lung nodule.
This trial tests a new natural killer (NK) cell therapy, NK510, for people with advanced non-small cell lung cancer who have already tried immunotherapy and it stopped working. The goal is to see if NK510 is safe and can shrink tumors or slow the cancer's growth.
This study looks at blood samples from people who have had a lung nodule removed but still have other nodules. The goal is to find patterns in immune cells and past viral infections that might help doctors better monitor or predict how these remaining nodules behave.
This study looks at the immune system using a special blood test to learn more about multiple lung nodules after surgery. It may help doctors better understand and monitor your condition over time.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy and a PD-1 inhibitor (a type of immunotherapy) before surgery can help shrink early-stage non-small cell lung cancer and improve outcomes. The goal is to see if this combination is safe and effective.
This study tests a blood test that helps doctors figure out if a lung nodule is likely to be cancer. The test may help avoid unnecessary procedures for people with suspicious but not clearly cancerous nodules.
Hear when a new Pulmonary Nodules, Solitary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.